The new journal represents EULAR's commitment to fostering scientific excellence and promoting the dissemination of high-quality, peer-reviewed research. As an open-access journal, it will ensure that cutting-edge studies, reviews, and insights are immediately available to a global audience, furthering the reach and impact of rheumatology research across disciplines.
"EULAR is thrilled to partner with Elsevier to offer a dynamic and accessible platform that supports the ongoing evolution of rheumatology research," - said Prof. Daniel Aletaha, EULAR President, - "By removing barriers to access, we are facilitating the exchange of knowledge, fostering collaboration, and empowering researchers and clinicians to drive forward innovations that will benefit patients worldwide."
Prof. Gerd Burmester, Editor-in-Chief of the new journal, added, "Our mission is to create a leading platform for disseminating high-quality research that will drive the field of rheumatology forward. We are committed to ensuring that the journal reflects the diversity and excellence of rheumatology research worldwide, and we look forward to welcoming contributions that will shape the future of care for people with rheumatic and musculoskeletal diseases (RMDs)."
The new open-access journal will cover a wide range of topics within rheumatology, including but not limited to:
- Clinical and Translational Research
- Epidemiology and Public Health
- Basic Science
- Advances in Treatment and Management
- Patient-Centred Care and Outcomes
- Paediatric Rheumatology
- Health Economics and Policy in Rheumatology
- Digital Health and Telemedicine
- Imaging and Biomarkers
- Comorbidities and Multidisciplinary Care
By leveraging Elsevier's advanced online platform, the journal will offer a seamless, user-friendly experience. The collaboration between EULAR and Elsevier underscores a shared commitment to excellence in scientific publishing and the advancement of knowledge in rheumatology. Authors will benefit from a streamlined submission process, rigorous peer review, and the opportunity to publish their work in a prestigious, widely recognised platform.
About EULAR
EULAR is the European umbrella organisation representing scientific societies, health professional associations and organisations for people with rheumatic and musculoskeletal diseases (RMDs). EULAR aims to reduce the impact of RMDs on individuals and society, as well as improve RMD treatments, prevention, and rehabilitation. To this end, EULAR fosters excellence in rheumatology education and research, promotes the translation of research advances into daily care, and advocates for the recognition of the needs of those living with RMDs by EU institutions.
About Elsevier
As a global leader in scientific information and analytics, Elsevier helps researchers and healthcare professionals advance science and improve health outcomes for the benefit of society. We do this by facilitating insights and critical decision-making with innovative solutions based on trusted, evidence-based content and advanced AI-enabled digital technologies.
We have supported the work of our research and healthcare communities for more than 140 years. Our 9,500 employees around the world, including 2,500 technologists, are dedicated to supporting researchers, librarians, academic leaders, funders, governments, R&D-intensive companies, doctors, nurses, future healthcare professionals and educators in their critical work. Our 2,900 scientific journals and iconic reference books include the foremost titles in their fields, including Cell Press, The Lancet and Gray’s Anatomy.
Together with the Elsevier Foundation, we work in partnership with the communities we serve to advance inclusion and diversity in science, research and healthcare in developing countries and around the world.
Elsevier is part of RELX, a global provider of information-based analytics and decision tools for professional and business customers. For more information on our work, digital solutions and content, visit www.elsevier.com.